Patent Expiry

Patent/Exclusivity Expiry: JELMYTO

Other upcoming events for URGN

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel For
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary C
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel For
Patent ExpiryPatent/Exclusivity Expiry: ZUSDURI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: JELMYTO — URGN Patent Expiry | BioSniper